AGC Biologics Expands Cell Therapy Development Operations to Asia to Serve Growing Market Need
TOKYO--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.'s Yokohama Technical Center, marking the latest step in the global expansion of the company's Global Cell and Gene Technologies Division. The improved geographical footprint allows AGC Biologics to better serve customers requiring autologous and allogeneic products across all markets, with cell therapy manufacturing now available in three continents (Milan, Italy – Longmont, Colorado, U.S. – Yokohama, Japan).
This new site precedes the opening of a new AGC Biologics Yokohama manufacturing facility on schedule to be operational in 2027 with pre-clinical through commercial services for mammalian-based protein biologics, cell therapies, and messenger RNA.
The Yokohama location will provide process transfer and manufacturing services for pre-clinical and clinical trials to serve an expanding global cell therapy market. Its core technologies include induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, and CAR-T cell therapies. AGC Biologics Cell and Gene Technology Center of Excellence in Milan, with its nine product approvals by the EMA and FDA, hundreds of batches manufactured, and 30-year track record, will support and enable the successful ramp up of operation in the new Yokohama site.
'In a cell and gene therapy market of high volatility and witnessing consolidation of CDMOs, AGC Biologics is among the few experiencing significant growth and success. We are now building on this success to complete the vision of having a truly global offering,' said Luca Alberici, Executive Vice President of Global Cell and Gene Technologies at AGC Biologics. 'Now Asian developers can benefit from having a local supply within one of the best global infrastructures on the market for cell therapy. Moreover, customers can continue to leverage the offering of viral vector central supply in our Milan facility, which supplies around a third of the ex vivo gene therapy product approved for commercialization. AGC Biologics, through its proprietary ProntoLVV and BravoAAV platforms, aims to offer viral vectors at a sustainable cost for its clients targeting less than 1,000€ per CAR-T patient.'
'Our team of friendly experts in Milan have a strong reputation for collaboration and working side-by-side with customers to achieve clinical, late-phase, and commercial successes,' said Jun Takami, Senior Vice President and General Manager, Japan Region and Yokohama Facility. 'As part of this next major phase for cell therapy in the region, our Yokohama team is ready to support partners in accelerating drug development timelines while maintaining the highest quality standards in the industry."
AGC Biologics is a part of AGC Inc.'s Life Science Company. The Life Science company operates over 10 facilities worldwide focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. The AGC Inc. Yokohama Technical Center, built in 2020, is dedicated to advancing AGC Inc.'s research and development capabilities in materials science, chemical processes, and biotechnology.
Please visit www.agcbio.com to learn more about AGC Biologics' global network of services for protein biologics and cell and gene therapies.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Accenture Report: European Firms Must Accelerate AI Adoption to Close Productivity Gap
MILAN--(BUSINESS WIRE)--European companies must strengthen the capabilities needed to scale AI faster if they are to address the growing productivity gap and enhance the region's overall competitiveness, according to a new report released by Accenture (NYSE:ACN). The study highlights that the average European worker now produces only 76% as much as their US counterparts, a significant decline from being on par 30 years ago, with persistent underinvestment in technology identified as a major cause. Despite the recent Draghi report into European competitiveness pointing to AI as a potential solution to Europe's productivity problems, Accenture's research found that European companies are yet to take full advantage of the AI opportunity. Currently more than half (56%) of the 800 large European companies surveyed have yet to scale a major AI investment. Yet if all large (€1 billion+) European companies enhanced their AI capabilities to match those of leading industries, Accenture found that almost €200 billion could be added to annual business revenues. Mauro Macchi, CEO of Accenture in EMEA, said: 'At a time when geopolitical uncertainties are on the rise, finding a solution to Europe's productivity gap has never been more crucial. AI provides a unique opportunity for Europe to reinvent its economy and significantly boost its competitiveness. European firms are making progress but need to further leverage cloud, modernize data architecture and focus on skilling in order to scale AI faster and unleash its full potential. A coordinated industrial strategy, including shared AI infrastructure and investments will also avoid dispersion of initiatives and help businesses across all European countries access powerful computing, R&D, and training. Europe has all it needs to take advantage of the AI revolution. Now is the time to execute on it.' The study found that large European companies are adopting AI more quickly than smaller companies, which could further impact Europe's productivity and competitiveness. Whilst nearly half (48%) of Europe's largest companies have scaled at least one transformational generative AI initiative, less than a third (31%) of smaller companies have. Europe has a higher concentration of smaller companies compared to the US, making this size of company a significant opportunity. AI adoption also varies across industries. Some sectors such as automotive, aerospace and defense are leading the way, while others, including telecommunications and utilities, lag behind. The report emphasizes that since these sectors provide critical regional infrastructure such as energy systems and digital networks, their relatively low AI maturity poses a competitiveness and sovereignty concern for the region. The industrial sector, which accounts for more than a quarter of Europe's GDP is also yet to tap into the full potential of AI. These disparities underscore the need for a more uniform approach to AI adoption across all industries. The report also identifies key capabilities, from data to talent, that companies need to drive value from AI investments. These AI capabilities are well spread across countries, with Switzerland, Germany, the UK and France, on average, home to slightly more AI-ready companies, than Italy and Spain. To fully realize the benefits of AI, the report calls for the development of a robust, competitive AI ecosystem in Europe. This includes helping smaller companies level up on AI, nurturing a sovereign European AI ecosystem, and developing a coordinated industrial strategy. Additionally, AI literacy and workforce development are critical, as many European workers (60%) are concerned about job displacement, and a third (36%) do not feel suitably trained to use AI efficiently. The report identifies several key barriers to scaling AI, including setting up a robust data foundation, building and maintaining multi-disciplinary teams, managing security and privacy risks, and demonstrating business value. To overcome these challenges, the report recommends: Data Foundation: Invest in breaking down data silos and building an end-to-end data foundation with quality data. Multi-Disciplinary Teams: Focus on talent development, including training and continuous learning opportunities, to build and maintain the necessary expertise. Security Risks: Adopt a secure digital core to reduce vulnerabilities, redundancy, and technical debt. Business Value: Identify and implement concrete use cases with proven ROI. AI Literacy: Provide more training and support to employees and ensure that AI tools are accessible and user-friendly. About Accenture Accenture is a leading global professional services company that helps the world's leading businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services—creating tangible value at speed and scale. We are a talent- and innovation-led company with approximately 791,000 people serving clients in more than 120 countries. Technology is at the core of change today, and we are one of the world's leaders in helping drive that change, with strong ecosystem relationships. We combine our strength in technology and leadership in cloud, data and AI with unmatched industry experience, functional expertise and global delivery capability. Our broad range of services, solutions and assets across Strategy & Consulting, Technology, Operations, Industry X and Song, together with our culture of shared success and commitment to creating 360° value, enable us to help our clients reinvent and build trusted, lasting relationships. We measure our success by the 360° value we create for our clients, each other, our shareholders, partners and communities. Visit us at
Business Wire
an hour ago
- Business Wire
OCEU President Harry Goslin to Join WSIB Strike Picket Line in Waterloo
WATERLOO, Ontario--(BUSINESS WIRE)--Harry Goslin, president of the Ontario Compensation Employees Union (OCEU/CUPE 1750), will join striking Workplace Safety and Insurance Board (WSIB) workers on the picket line outside the constituency office of NDP MPP Catherine Fife at 100 Regina St. S. in Waterloo on Thursday, June 26 at 10:00 a.m. His appearance follows a renewed call from the union for WSIB leadership to finalize a fair deal before Canada Day, as the strike by more than 3,600 frontline workers stretches over two months. Where: Constituency office of MPP Catherine Fife — 100 Regina St. S., Waterloo Time 10:00 a.m. ET 'This strike cannot drag on any longer,' said Goslin. 'The WSIB has delayed long enough. Our bargaining team is a fully empowered decision-making body. What's missing is a mandate from WSIB leadership — especially the CEO — to finalize a deal and end this disruption.' These essential workers process injury claims, support safe return-to-work plans and deliver critical services to injured Ontarians. Despite repeated efforts by the union to reach a resolution, WSIB leadership has not tabled a final offer or allowed a member vote. 'We're calling on the WSIB to pull out all the stops and get this done before Canada Day,' said Goslin. 'It's time to finish the deal — and restore stability for injured workers across Ontario.' The union's team remains ready 24/7 to reach a settlement. Meanwhile, system breakdowns and mounting service delays have underscored the impact of the ongoing strike. mb/cope491
Business Wire
an hour ago
- Business Wire
CUPE National President Mark Hancock to Join WSIB Picket Line in Ottawa
OTTAWA, Ontario--(BUSINESS WIRE)--Mark Hancock, National President of the Canadian Union of Public Employees (CUPE), will join striking Workplace Safety and Insurance Board (WSIB) workers on the picket line outside 1580 Merivale Road, Unit 500 in Ottawa on Thursday, June 26, between 12:00 and 1:00 p.m. ET. Hancock's visit comes as more than 3,600 WSIB frontline staff continue a province-wide strike that has now stretched beyond two months — the first strike in the organization's 110-year history. The picket will take place in front of the constituency office of Ottawa West–Nepean MPP Chandra Pasma, as part of a broader effort to raise public and political awareness of the urgent need for leadership from WSIB decision-makers. Where: 1580 Merivale Road, Unit 500 (MPP Chandra Pasma's constituency office) Time Between 12:00 and 1:00 p.m. 'We're grateful to have CUPE National President Mark Hancock join us in Ottawa,' said Harry Goslin, President of the Ontario Compensation Employees Union (OCEU/CUPE 1750). 'His support sends a powerful message — this deal should have been done weeks ago, and the delay lies squarely with WSIB leadership. What's missing is the mandate from the CEO and Board to bring this strike to a fair conclusion.' Despite good-faith efforts and ongoing mediated talks, WSIB has refused to table a final offer. The union's bargaining team remains ready to reach a fair settlement — 24 hours a day, seven days a week. 'We're calling on the WSIB to pull out all the stops and get this done before Canada Day,' said Goslin. 'It's time to finish the deal — and restore stability for injured workers across Ontario.' mb/cope491
